Chester Ridgway.

Paul W. Ladenson, M.D all reviews here ., Jens D. Kristensen, M.D., Ph.D., E. Chester Ridgway, M.D., Anders G. Olsson, M.D., Ph.D., Bo Carlsson, M.Sc., Irwin Klein, M.D., John D. Baxter, M.D., and Bo Angelin, M.D., Ph.D.: Usage of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia The association between elevated degrees of circulating low-density lipoprotein cholesterol and an elevated risk of atherosclerotic coronary disease is well established,1 as will be the reductions in both degrees of serum cholesterol and the risk of coronary disease that occur by using inhibitors of hepatic 3-hydroxy-3-methyl-glutaryl coenzyme A reductase.1 However, the efficacy of statins is limited if stringent goals for serum LDL cholesterol amounts aren’t achieved2 in patients receiving statins alone3 or if side effects develop that require a dose reduction or discontinuation of the agent.4 Furthermore, statins are less effective in lowering levels of other lipoproteins, such as triglycerides5 and Lp lipoprotein,6 that are associated with the risk of atherosclerotic vascular disease.9 Consequently, additional agents that target the metabolism of lipoproteins to improve outcomes in patients with cardiovascular disease will be beneficial.

The subjects were recruited from the New Haven community by local advertisement, with the use of the same inclusion and exclusion criteria which were put on the Asian Indian subjects. The foundation-10 logarithm of liver triglyceride, the natural logarithm of plasma triglyceride, and levels of plasma apolipoprotein C3 were then adjusted for body-mass and age index through linear regression. To check for association under an additive model, two strategies were used: a linear-regression trend test for correlation with the genotypes at rs2854116 and rs2854117 and a one-way evaluation of variance.